ONCOLYTICS BIOTECH INC (ONCY)
CA6823108759 - Common Stock
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the...
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
/PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood...
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the first quarter of 2024.
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncolytics Biotech (NASDAQ:ONCY) just reported results for the first quarter of...
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
/PRNewswire/ -- The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq ® ) combination expands existing pancreatic cancer program First patient expected to be enrolled in Q2 2024 San Diego, CA & Calgary, AB – May 9, 2024 – Oncolytics Biotech ® Inc. (NASDAQ: […]
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, will commence...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today...
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
/PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging."...
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032
/CNW/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further...
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
/PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising...
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response
/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the...
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END
Biotech Innovations Paving the Way in Breast Cancer Fight
/PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases,...
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial expected in H2 2024 San Diego, CA and Calgary, AB – April 11, 2024 – Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: […]
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to...
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is...
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that President...
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that...
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Biotech's Role in Addressing the Pancreatic Cancer Emergency
/PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers...
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
ONCY stock results show that Oncolytics Biotech beat analyst estimates for earnings per share the fourth quarter of 2023.
ONCY Stock Earnings: Oncolytics Biotech Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncolytics Biotech (NASDAQ:ONCY) just reported results for the fourth quarter o...
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with...
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with...